Mental health & addiction

Progress on mental health and addiction is real — and often underreported. This archive covers treatment breakthroughs, policy shifts, community-led programs, and research advances that are improving lives. It’s evidence that change is possible.

Golden Gate Bridge, for article on Golden Gate Bridge suicide prevention net

Suicide-prevention net beneath Golden Gate Bridge completed

The Golden Gate Bridge now has a continuous stainless steel safety net running the full 1.7-mile span, suspended 20 feet below the deck where drivers can’t see it. As the net neared completion in 2023, the number of people who jumped fell by more than half — a quiet but powerful early sign that it’s working. The project was driven by the Bridge Rail Foundation, a small group of parents who lost children at the bridge and refused to give up over more than 18 years of advocacy. Their win is a reminder that thoughtful design, backed by evidence and persistence, can turn even the most heartbreaking places into something safer for everyone who comes next.

Empty bottles of alcohol, for article on psilocybin-assisted therapy

First-of-its-kind study reveals how psilocybin helps treat alcohol dependence

Psilocybin-assisted therapy helped 13 people who had struggled with heavy drinking reach the root of what they were drinking to escape, according to new interviews published in Psychology of Addictive Behaviors. Participants described years of self-blame and isolation quieting after their sessions, replaced by something many had never felt toward themselves: compassion. They credited the trained therapists and carefully held setting as much as the medicine itself, calling both essential to feeling safe enough to face old pain. The researchers are honest about the study’s limits, including a mostly white, higher-income participant group. Still, as Oregon and Colorado open legal pathways, these first-person accounts offer a hopeful glimpse of how psychedelic care might one day reach the communities who need healing most.

Dried psilocybin mushrooms on a surface for an article about psilocybin therapy legalization in New Mexico, for article on Oregon psilocybin facilitators

Oregon licenses U.S.’s first-ever legal psilocybin facilitators

Oregon licensed its first three psilocybin facilitators in April 2023, making it the first U.S. state to formally authorize practitioners to guide adults through psychedelic sessions at regulated service centers. The approvals were part of a much larger pipeline, with more than 300 permit and license applications already submitted and the state’s first psilocybin manufacturer licensed the month prior. Voters had approved this supervised-access model back in 2020, choosing a path that doesn’t require a prescription or diagnosis but does require trained guidance. Real hurdles remain, including local bans in over 100 Oregon cities and open questions about affordability. Still, this is the first legal home in the country for a therapy that researchers increasingly believe could transform how we treat depression, anxiety, and trauma.

Welcome to Oregon sign amidst evergreen trees, for article on psilocybin license

Oregon approves the U.S.’s first legal psilocybin mushroom farms

Legal psilocybin mushrooms are now being grown in Oregon for the first time in over 50 years of U.S. prohibition, with Satori Farms PDX becoming the first licensed producer in the country. Owner Tori Armbrust, a longtime gourmet mushroom grower, plans to supply two service centers within months, where trained facilitators will guide adults through supervised sessions. The framework, approved by Oregon voters in 2020, has already drawn more than 200 license and worker permit applications, and the first cohort of state-trained facilitators has graduated. Cost and federal scheduling remain real hurdles, but Oregon is quietly turning a decade of promising mental health research into the country’s first working model — one that other states, and people struggling with treatment-resistant depression, will be watching closely.

Narcan nasal spray, for article on OTC naloxone

U.S. FDA approves over-the-counter sale of overdose reversal drug Narcan

Over-the-counter Narcan is now a reality: the FDA cleared the 4 mg naloxone nasal spray for sale at pharmacies, convenience stores, and other retailers without a prescription — the first opioid overdose reversal drug ever to earn that status in the U.S. The medication works within minutes to restore breathing, and it’s safe enough that any bystander can use it, no medical training required. For years, harm reduction workers quietly distributed naloxone in their communities, knowing how much it mattered; this decision finally meets them where they’ve been standing. Putting a life-saving tool on the same shelf as aspirin won’t end the overdose crisis on its own, but it’s a powerful reminder that expanding access — trusting ordinary people to help each other — is how public health movements actually save lives.